Oswald Clark: In December, the U.S. Supreme Court announced it will review the Food and Drug Administration’s 2000 approval of the abortion drug mifepristone and subsequent liberalization of regulations by the Biden administration. In 2000, the Food and Drug Administration (FDA) under pressure from the Clinton administration and abortion advocates, allowed the two-pill abortion drug regimen (mifepristone and misoprostol) then known as […]
You are unauthorized to view this entire article. Please log in to your account to receive full access to The Interim.
